Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development

Gałecki, Piotr; Gałecka, Elżbieta; Maes, Michaël; Orzechowska, Agata; Berent, Dominika; Talarowska, Monika; Bobińska, Kinga; Lewiński, Andrzej; Bieńkiewicz, Małgorzata; Szemraj, Janusz

doi:10.1016/j.pnpbp.2013.04.011

Cited by 26 publications

(23 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we re-included one article in the meta-analysis of correlations between VEGF and severity of disease (Isung et al, 2012). The results of the literature search are listed in Table 1 (Berent et al, 2014;Carvalho et al, 2014Carvalho et al, , 2013Clark-Raymond et al, 2014;Dalby et al, 2013;Dome et al, 2009;Elfving et al, 2014;Fornaro et al, 2013;Galecki et al, 2013a;Kahl et al, 2009;Kotan et al, 2012;Lee and Kim, 2012;Lu et al, 2013;Schweiger et al, 2008;Takebayashi et al, 2010;Ventriglia et al, 2009). …”

Section: Studies Included In the Current Meta-analysismentioning

confidence: 99%

“…Similarly, during step 3, we subdivided the studies according to the sample source used in the studies into the serum sample subgroup (Berent et al, 2014;Carvalho et al, 2014Carvalho et al, , 2013Elfving et al, 2014;Galecki et al, 2013a;Kahl et al, 2009;Kotan et al, 2012;Schweiger et al, 2008;Ventriglia et al, 2009) and the plasma sample subgroup (ClarkRaymond et al, 2014;Dalby et al, 2013;Dome et al, 2009;Fornaro et al, 2013;Lee and Kim, 2012;Lu et al, 2013;Takebayashi et al, 2010 …”

Section: Meta-analysis Of Vegf Using Serum or Plasma Samplesmentioning

confidence: 99%

“…We could not perform the meta-analysis for subgroups (iii) and (iv) as described in Section 2.4, because too few reports provided detailed information of the current disease state (Takebayashi et al, 2010) or the number of episodes (Dalby et al, 2013;Galecki et al, 2013a).…”

Section: Subgroups Of Meta-analysis Of Vegf Using the Other Clinical mentioning

confidence: 99%

“…Isung and colleagues recruited a group who had attempted suicide, most of whom fulfilled the diagnosis of mood disorders in DSM (Diagnostic and Statistical Manual of Mental Disorders) axis I, and found lower VEGF levels in their cerebrospinal fluid than in healthy controls (Isung et al, 2012). In addition, many studies have demonstrated an increase in peripheral VEGF in MDD patients compared with healthy controls, either in serum (Berent et al, 2014;Carvalho et al, 2014;Elfving et al, 2014;Galecki et al, 2013a;Kahl et al, 2009;Schweiger et al, 2008) or plasma (Lee and Kim, 2012;Lu et al, 2013;Takebayashi et al, 2010). However, some studies have reported inconsistent findings.…”

Section: Introductionmentioning

confidence: 99%

“…Berent et al, 2014;Carvalho et al, 2014;Clark-Raymond et al, 2014;Fornaro et al, 2013;Kahl et al, 2009;Kotan et al, 2012;Lee and Kim, 2012;Ventriglia et al, 2009) and non-drug free subgroup(Carvalho et al, 2013;Dalby et al, 2013;Dome et al, 2009;Elfving et al, 2014;Galecki et al, 2013a;Lu et al, 2013;Schweiger et al, 2008;Takebayashi et al, 2010)…”

mentioning

confidence: 99%

See 4 more Smart Citations

Increased levels of vascular endothelial growth factor in patients with major depressive disorder: A meta-analysis

Tseng¹,

Cheng²,

Chen

et al. 2015

European Neuropsychopharmacology

View full text Add to dashboard Cite

Section: Studies Included In the Current Meta-analysismentioning

confidence: 99%

Section: Meta-analysis Of Vegf Using Serum or Plasma Samplesmentioning

confidence: 99%

Section: Subgroups Of Meta-analysis Of Vegf Using the Other Clinical mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Increased levels of vascular endothelial growth factor in patients with major depressive disorder: A meta-analysis

Tseng¹,

Cheng²,

Chen

et al. 2015

European Neuropsychopharmacology

View full text Add to dashboard Cite

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

Maffioletti

Gennarelli

Magri

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Alterations in peripheral vascular endothelial growth factor (VEGF) levels were observed in major depressive disorder and relative treatments and were shown to be influenced by genetic variants. The study objective was to explore, at a genome‐wide level, possible interplaying effects between the genetic background and major depressive disorder in regulating VEGF levels. Moreover, we aimed to investigate the association between these variants and response to electroconvulsive therapy. A genome‐wide association study was carried out both on controls and patients with major depressive disorder (n = 145; n = 121) in correlation with serum VEGF levels determined by ELISA. Five SNPs not included in SNP arrays were additionally genotyped. Seventy‐one patients with treatment‐resistant depression underwent electroconvulsive therapy and were evaluated as responders/nonresponders. An association between VEGF levels and a locus in 6p21.1, downstream the VEGF gene, was evidenced both in controls (best SNP: FDR‐corrected p = 2.4 × 10−5) and in patients with major depressive disorder (best SNP: FDR‐corrected p = 2.6 × 10–3). The alleles associated with lower VEGF concentrations in patients were also associated with nonresponse to electroconvulsive therapy (p = .01). These results confirm a role of SNPs in 6p21.1 locus as major influencers of circulating VEGF levels also in patients affected by major depressive disorder and indicate a possible implication in response to electroconvulsive therapy.

show abstract

An astroglial basis of major depressive disorder? An overview

Wang

Jie

Liu

et al. 2017

Glia

172

125

View full text Add to dashboard Cite

Depression is a chronic, recurring, and serious mood disorder that afflicts up to 20% of the global population. The monoamine hypothesis has dominated our understanding of the pharmacotherapy of depression for more than half a century; however, our understanding of the pathophysiology and pathogenesis of major depression has lagged far behind. Astrocytes are the most abundant and versatile cells in the brain, participating in most, if not all, of brain functions as both a passive housekeeper and an active player. Mounting evidence from clinical, preclinical and post-mortem studies has revealed a decrease in the number or density of astrocytes and morphological and functional astroglial atrophy in patients with major depressive disorder (MDD) and in animal models of depression. Furthermore, currently available antidepressant treatments at least partially exert their therapeutic effects on astrocytes. More importantly, dysfunctional astrocytes lead to depressive-like phenotypes in animals. Together, current studies point to astroglial pathology as the potential root cause of MDD. Thus, a shift from a neuron-centric to an astrocyte-centric cause of MDD has gained increasing attention during the past two decades. Here we will summarize the current evidence supporting the hypothesis that MDD is a disease of astrocyte pathology and highlight previous studies on promising strategies that directly target astrocytes for the development of novel antidepressant treatments.

show abstract

Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development

Cited by 26 publications

References 55 publications

Increased levels of vascular endothelial growth factor in patients with major depressive disorder: A meta-analysis

Increased levels of vascular endothelial growth factor in patients with major depressive disorder: A meta-analysis

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

An astroglial basis of major depressive disorder? An overview

Contact Info

Product

Resources

About